Breast-Specific Gamma Imaging Cost-Effective for Presurgical Planning

"BSGI proved to be a cost-effective breast diagnostic imaging modality, able to detect mammographically occult breast cancers and provide comparable sensitivity to MRI at a higher patient compliance rate and lower cost,” said Dr. Margaret Bertrand, director of breast imaging at Solis Bertrand Breast Center (Greensboro, NC, USA).

In this study, BSGI was performed prior to needle biopsy on 123 patients with 126 breast carcinomas who subsequently had a postbiopsy, preoperative breast MRI for surgical planning in accordance with the ACS guidelines. BSGI and MRI both detected 123 of the 126 malignancies, yielding a sensitivity of 97% for both studies. Eleven percent of the tumors found with BSGI were detected in patients with equivocal or negative mammograms. Four patients with cancer were excluded from the study because they were unable to undergo breast MRI. The cost for conducting BSGI in this group of patients was US$37,321 compared to the cost for conducting breast MRI in this group was $122,314.

BSGI for the study was conducted using a Dilon 6800 gamma camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. BSGI is a molecular breast imaging technique that can visualize lesions independent of tissue density and target very early stage tumors. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and typically appear as focal areas on the BSGI image.

Dilon Diagnostics' (Newport News, VA, USA) cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI.

Related Links:
Solis Bertrand Breast Center
Dilon Diagnostics